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Abstract
Purpose—To characterize the risk and risk factors for intraocular pressure (IOP) elevation in 
pediatric non-infectious uveitis.
Design—Multi-center retrospective cohort study.
Participants—Nine hundred sixteen children (1593 eyes) <18 years old at presentation with 
non-infectious uveitis followed between January 1978 through December 2007 at five academic 
uveitis centers in United States.
Methods—Medical records review by trained, certified experts.
Main outcome measures—Prevalence and incidence of IOP≥21 and ≥30mmHg and incidence 
of a rise in IOP by ≥10mmHg. To avoid under ascertainment, outcomes were counted as present 
when IOP-lowering therapies were in use.
Results—Initially 251 (15.8%) and 46 eyes (2.9%) had IOP≥21 and ≥30mmHg, respectively. 
Factors associated with presenting IOP elevation included age 6–12 years (versus other pediatric 
ages), prior cataract surgery (adjusted odds ratio≥21mmHg [aOR21]=2.42, P=0.01), pars plana 
vitrectomy (adjusted odds ratio≥30mmHg[aOR30]=11.1, P=0.03), duration of uveitis ≥6 months 
(aORs30 up to 11.8, P<0.001), contralateral IOP elevation (aOR21=16.9, aOR30=8.29; each 
P<0.001), visual acuity worse than 20/40 (aORs21 up to 1.73, P=0.02; aORs30 up to 2.81 
P=0.03), and topical corticosteroid use (aORs up to 8.92, P<0.001 in a dose-response 
relationship).
The median follow-up was 1.25 years (interquartile range 0.4–3.66). The estimated risk of any 
observed IOP elevation to ≥21 mmHg, ≥30 mmHg and of a rise in IOP by ≥10mmHg was 33.4%, 
14.8% and 24.4% respectively within 2 years. Factors associated with IOP elevation included pars 
plana vitrectomy (adjusted hazard ratio≥21mmHg[aHR21]=3.36, P<0.001), contralateral IOP 
elevation (aHRs up to 9.54, P<0.001), the use of topical (aHRs up to 8.77 that followed a dose-
response relationship, P<0.001), periocular (aHRs up to 7.96, P<0.001) and intraocular (aHRs up 
to 19.7, P<0.001) corticosteroids.
Conclusions—IOP elevation affects a large minority of children with non-infectious uveitis. 
Statistically significant risk factors include IOP elevation or use of IOP-lowering treatment in the 
contralateral eye and local corticosteroid use – that demonstrated a dose-and route of 
administration-dependent relationship. In contrast, use of immunosuppressive drug therapy did 
not increase such risk. Pediatric eyes with non-infectious uveitis should be followed closely for 
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IOP elevation when strong risk factors such as the use of local corticosteroids and contralateral 
IOP elevation are present.
Keywords
pediatric; uveitis; intraocular pressure; risk; risk factor; glaucoma; ocular hypertension; 
corticosteroid; incidence; prevalence
Introduction
Since Joseph Beers first reported an association between uveitis and glaucoma in 1813, 1 the 
irreversible blindness caused by uveitic glaucoma has remained an important complication 
of pediatric uveitis impacting the length of morbidity-indicative disability adjusted life 
years. 2 Although several potential factors contributing to optic nerve damage are under 
investigation, 3–6 intraocular pressure (IOP) elevation is a predominant modifiable risk 
factor. The risk of glaucomatous optic neuropathy in open angle glaucoma has been reported 
to increase in a non-linear fashion at higher pressures, approaching 100% when IOP was 
≥35mmHg. 7,8 The Multicenter Uveitis Steroid Treatment (MUST) Trial has demonstrated 
that 24% of uveitic eyes that manifested IOP rise by ≥10mmHg, developed glaucomatous 
optic neuropathy within 2 years. 9
Available information regarding the prevalence and incidence of IOP elevation in pediatric 
uveitis cases varies widely; estimates among various pediatric uveitic subpopulations were 
found to range between 3–51%. 10–12 Synthesis of these reports has limitations given that 
the existing data involved smaller subpopulations with a limited study power, variable 
lengths of follow-up, disparate criteria for age limits and discordant definitions for IOP 
elevation. None of the reports exclusively describes the risk of IOP elevation in pediatric 
non-infectious uveitic populations.
To better characterize the potential risk of IOP elevation in pediatric non-infectious uveitis 
and to describe potentially predictive risk factors thereof, we conducted a study in 
children<18 years of age at presentation belonging to the large Systemic 
Immunosuppressive Therapy for Eye Diseases (SITE) non-infectious uveitis study cohort 
that received subspecialty care over a 30-year period in the United States.
Methods
The study adhered to tenets of the Declaration of Helsinki. Governing Institutional Review 
Boards of participating institutions approved inclusion of patients both living and deceased 
with waiver of informed consent for this retrospective review.
Study Population
Data for this report were abstracted from the parent SITE Cohort Study database–the study 
design of which has been described elsewhere. 13 Patients with infectious uveitis & AIDS 
had been excluded from the parent cohort. For this analysis, all patients <18 years of age at 
presentation with non-infectious uveitis followed at five academic ocular-inflammation 
centers in the United States between January 1978 through December 2007 were included.
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Comprehensive patient records were reviewed by trained certified experts to obtain pertinent 
data that related to each eye at every visit recorded based on external, slit-lamp and dilated 
fundus examinations, tonometric measurements and methods, angiography and optical 
coherence tomography (when indicated), each medication in use and operative records (each 
used when indicated per clinical judgment) that were entered into a customized, real-time, 
error-correcting Microsoft Access database (Microsoft Corporation, Redmond, WA).
Main outcome measures
The primary outcomes assessed were prevalence of IOP≥21 and ≥30mmHg. In outcome-
naïve eyes at presentation, the incidence of IOP≥21 and ≥30, and a rise by ≥10mmHg were 
evaluated over time. To avoid under-ascertainment, all of these outcomes were counted as 
present when IOP-lowering therapy was found to be in active use at any subsequent follow-
up visit, on the presumption that these eyes had exhibited IOP elevation during the interim 
that required treatment with IOP-lowering medications or surgery by collaborating 
ophthalmologists. 14
Potential associations were evaluated between outcomes and age, gender, race, smoking 
status, relevant systemic inflammatory and non-inflammatory diseases, intraocular surgery, 
anatomical location of inflammation according to the International Uveitis Study Group 
criteria, 15,16 duration and laterality of uveitis, contralateral IOP elevation, hypotony 
(ipsilateral and contralateral), visual acuity, markers of ocular inflammatory activity graded 
in a manner similar to Standardization of Uveitis Nomenclature working group and the 
National Eye Institute grading criteria for vitreous haze, 17–19 uveitic structural 
complications and use of immunosuppressive drug therapy and corticosteroids. Prednisone- 
and topical prednisolone acetate 1%-equivalent dosages of all alternative systemic and 
topical corticosteroids used during the course of management were calculated to facilitate 
comparisons. Periocular and intraocular corticosteroids typically included dosages of 40 mg 
and 4 mg of triamcinolone acetonide, respectively.
Covariates missing at any visit were imputed by carrying the last recorded value forward. 
Visits lacking IOP records were censored, because the outcome could not be studied. 
Because cataract is objectively difficult to define in a retrospective chart review due to 
incomplete and non-standardized documentation, we limited our attention to cataract 
surgery, which can be well ascertained by chart review and is a reasonable surrogate for 
cataract. Due to concerns that the pathophysiology of IOP elevation may differ during early 
postoperative periods, data obtained from eyes within one month of the post cataract, pars 
plana vitrectomy and retinal detachment surgical period were excluded; however subsequent 
data were retained.
Based on pathogenesis considerations; IOP elevation in the contralateral eye and the 
presence of uveitis in the contralateral eye, each might be predictive of IOP elevation in the 
ipsilateral eye independent of each other. Hence these variables were analyzed separately.
When appropriate, time-updated covariates were used: for the level of current inflammatory 
activity, use of treatments, and the presence of complications of inflammation. For instance, 
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the time-updated level of activity would reflect something like the instantaneous effect of 
activity on IOP, rather than the cumulative effects of inflammation over the years (the latter 
perhaps better captured by the presence of complications of inflammation). Regarding such 
complications, once peripheral anterior synechia, posterior synechia and band keratopathy 
were noted, we considered them to be present throughout the course of follow up (time-
updated covariates which could only transition from absent to present). The rationale for this 
approach was that even if some of these were clinically noted to be absent at subsequent 
visits (such as after cataract surgery or EDTA chelation), the damage to the eye already had 
occurred. The short-run effects of local corticosteroid injections on IOP elevation are 
observed infrequently after a period of three months subsequent to the procedure. Hence 
outcomes that occurred only within three months of application of periocular and 
intravitreous corticosteroids were attributed to the procedure.
Statistical method and analyses
The prevalence of IOP elevation was evaluated based on the proportion with each event of 
interest. The relationships between prevalent IOP elevation and potentially associated 
factors were evaluated using crude and adjusted odds ratios (ORs) calculated using logistic 
regression that incorporated generalizations of generalized estimating equations to account 
for correlation between the eyes of individual patients. 20 The relationships between incident 
IOP elevation and potentially associated factors were evaluated using crude and adjusted 
hazard ratios (HRs) calculated using Cox proportional hazards models with a robust 
sandwich estimate to account for correlation between the eyes of individual patients. 21 Final 
multiple logistic regression and Cox regression models adjusted for covariates that were 
associated with the outcome in two or more of the five crude analyses (two for prevalence, 
three for incidence). The same covariates were used in multiple regression for prevalence 
and incidence models, except that time-updated variables requiring knowledge of the past 
(e.g., prior corticosteroid injections) were available only for the incidence models. The 
values of time-updated variables other than periocular and intravitreous corticosteroids were 
updated at every observation and their value at the time of the outcome observation was 
used. Since intravitreous corticosteroids were rarely applied, the fraction of eye-years 
associated with outcomes was of insufficient magnitude to be used as an adjustment factor 
in the statistical model.
Two-year incidence estimates were evaluated by calculating the cumulative incidence 
estimated from the crude Cox regression hazard function that allowed nonlinear IOP 
elevation rates and confidence intervals consistent with the hazard ratios and accounting for 
correlation between eyes of the same patient. Each outcome (≥21, ≥30, rise by ≥10mmHg) 
was modeled independently for both prevalence and incidence analyses; 95% confidence 
intervals were presented for all point estimates following the convention where the lower 
and upper bounds of the confidence interval are presented as subscripts before and after the 
estimate respectively.22 All statistical analyses were performed with SAS software version 
9.4 (SAS Inc., Cary, NC).
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IOP elevation at presentation and potential risk factors
Among 1593 eyes (916 children) at cohort entry, 251 (15.8%) and 46 (2.9%) eyes presented 
with IOP≥21 and ≥30mmHg, respectively. IOP measurements were recorded using 
Goldmann applanation tonometer, pneumotonometer, Tonopen, Schiotz and other methods 
in 56%, 30%, 13.7%, 0.04% and 0.29% of eyes, respectively.
The distribution of particular covariates as noted at presentation, that we judged were of 
most clinical interest or were adjusted for in the statistical model have been summarized in 
Table 1. Eye-specific data are used, given that most characteristics are eye-specific. The 
distributions from a patient level perspective were similar. A comprehensive summary of all 
covariates studied is given as Table 2, available at http://aaojournal.org, for those interested 
in association results for other variables.
Demographic characteristics demonstrated little association with IOP outcomes except that 
eyes of children 6–12 years of age were more likely to present with IOP≥21mmHg (adjusted 
overall P=0.07) and IOP≥30mmHg (adjusted overall P=0.007) when compared with eyes in 
other age groups. Regarding systemic disease associations, eyes of uveitic children did not 
demonstrate any risk of presenting IOP elevation or else the risk was not consistently 
present in both the crude and adjusted analysis (see Table 2, available at http://
aaojournal.org for more details).
Regarding clinical characteristics, 30.5% of pediatric eyes that previously had undergone 
cataract surgery were noted to have a 2.5 fold risk of presenting with IOP≥21mmHg 
(adjusted odds ratio≥21mmHg [aOR21]=1.192.424.92, P=0.01) when compared those eyes 
that did not have cataract surgery performed prior to referral. The higher odds associated 
with presenting IOP≥30mmHg in eyes that had prior cataract surgery was not found to be 
significant on adjusting for other factors, although the pattern of association was similar to 
that for the IOP≥21 mmHg outcome. In eyes that had undergone pars plana vitrectomy 
(other than for retinal detachment), the statistical significance of the crude association with 
presenting IOP≥21mmHg did not persist after accounting for other factors; but eyes of 
uveitic children were 11-fold more likely to present with IOP≥30mmHg (adjusted odds 
ratio≥30mmHg [aOR30]=1.3011.194.6, P=0.03). Pediatric eyes that had undergone retinal 
detachment surgery prior to presentation did not demonstrate such risk (all adjusted P 
values>0.1).
IOP≥21mmHg was noted in 16.9%, 13.1%, 20.4% and 16.2% of eyes, and IOP≥30mmHg in 
3.7%, 2.1% 1.8% and 2.4% of eyes with anterior, intermediate, posterior and panuveitis, 
respectively. Although these differences were overall statistically significant in the crude 
analysis, the association was abrogated on adjusting for other factors. Adjusted for other 
factors, pediatric eyes with bilateral uveitis had one-half and one-third less odds of 
presenting with IOP≥21 and ≥30mmHg, respectively (aOR21=0.330.510.80, P=0.003; 
aOR30=0.150.320.69, P=0.004), when compared with eyes with unilateral involvement. 
When compared with those having a uveitis duration <6 months, children with a longer 
duration (≥6 months) of uveitis had higher risk of presenting IOP≥21mmHg that was not 
Kothari et al. Page 6













found to be statistically significant on accounting for other factors. However, the risk 
associated with presenting IOP≥30mmHg was more pronounced, progressively increasing 
with longer duration of uveitis; reaching up to 11.8-fold in those eyes with uveitis of ≥5year 
duration (aORs30 up to3.3211.841.9, P<0.001).
Uveitic eyes of children that were on IOP-lowering treatment in the contralateral eye had a 
strong risk of presenting with IOP elevation: 38.2% and 12.5% of such uveitic eyes had 
IOP≥21 (aOR21=9.4616.930.1, P<0.001) and ≥30 mmHg (aOR30=3.168.2921.7, P<0.001), 
respectively.
Pediatric uveitic eyes with worse visual acuity were more likely to present with IOP 
elevation; each category of progressively worse visual acuity was associated with 
progressively higher IOP (see Tables 1).
Current activity of inflammation as manifested by: anterior chamber cells was associated 
with lower odds of IOP≥21 and ≥30mmHg and vitreous cells associated with lower odds of 
IOP≥21mmHg; in a dose-response relationship. Eyes with vitreous snowballs had lower 
crude odds of presenting IOP elevation, but this association did not persist on adjusting for 
other covariates. Other inflammatory markers followed a similar pattern, but most specific 
associations were not significant after adjusting for other factors. Presence of keratic 
precipitates (aOR21=0.190.310.5, P<0.001, aOR30=0.150.391.02, P=0.055) was associated 
with one-third lower odds of presenting IOP elevation. Regarding structural complications 
of uveitis, the higher crude odds of presenting IOP elevation associated with eyes having 
peripheral anterior synechiae, posterior synechiae and band keratopathy were no longer 
found to be significant after adjusting for other factors.
Use of systemic immunosuppressive therapy and systemic corticosteroids were not 
significantly associated with a higher risk of presenting with IOP elevation after adjusting 
for other factors including use of topical corticosteroids. However, use of topical 
corticosteroids was a strong risk factor for presenting IOP elevation–even doses of 1–2 
drops/day were associated with substantially higher risk, and higher doses tended to have 
progressively higher risk that reached up to ~9-fold (see Table 1).
A sensitivity analysis regarding presenting IOP elevation limited to eyes where IOP had 
been measured using applanation tonometry yielded similar results.
Incidence of IOP elevation over 2 years and potential risk factors
Eyes of children that were outcome-naïve at presentation were followed for a median of 1.25 
years (interquartile range 0.4–3.66). During follow-up, a high frequency of IOP elevation 
events were observed; 27.933.438.5% eyes developed IOP≥21mmHg, 10.714.818.7% 
developed IOP≥30mmHg and 19.724.428.8% of eyes developed a rise by ≥10mmHg within 2 
years of presentation to uveitis sub-specialty care. The proportion of eyes with IOP elevation 
(cumulative incidence) continued to rise throughout follow-up (see Figure 1), but the rate of 
rise (reflecting the incidence rate) tended to decline over follow-up time.
The relationship between potential risk factors (that were of clinical interest or adjusted for 
in the statistical model) and IOP elevation events is given as Table 3, and a complete 
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summary of all the variables studied is given as Table 4 (available at http://aaojournal.org). 
There were several differences in the risk factor association pattern between the prevalence 
and incidence analyses regarding demographic and diagnostic features. During follow-up, 
none of the demographic characteristics or systemic disease associations were associated 
with an alteration in risk of developing IOP elevation or the statistical significance of the 
association was found to be inconsistent across the crude and adjusted analyses.
In contrast to the results of the prevalence analysis, the higher crude hazard noted in eyes 
that had undergone cataract surgery prior to or during the course of the study was no longer 
significant after accounting for other variables. Eyes that had pars plana vitrectomy 
performed either prior to or during the course of management at a participating center, had 
~3-fold higher adjusted incidence (adjusted hazard ratio≥21mmHg[aHR21]=1.753.366.45, 
P<0.001) of IOP≥21mmHg; did not demonstrate a higher risk for developing IOP elevation 
of ≥30mmHg and the higher crude hazard noted with ≥10mmHg rise was not found to be 
significant after adjusting for other variables (adjusted P values>0.1). On average, eyes that 
had undergone retinal detachment surgery did not have increased incidence of IOP 
elevation.
The risk of developing IOP elevation by anatomical location, laterality and duration of 
uveitis either did not vary or else did not show consistent association across crude and 
adjusted analyses.
Eyes of patients in whom the fellow eye was found to have IOP elevation or needed IOP-
lowering medications or surgery were associated with ~9.5-fold higher adjusted incidence 
(aHRs up to 1.959.5446.7, P<0.001) of IOP elevation. Similar to the pattern observed at 
presentation, progressively higher levels of contralateral IOP elevation were associated with 
increasing propensity for developing progressively worse ipsilateral IOP elevation in a step-
wise manner (see Figure 2). The absolute risks of developing IOP elevations of ≥21, ≥30 
and rise by ≥10mmHg in the ipsilateral eye when the contralateral eye had IOP≥30mmHg 
were 64%, 58%, and 57% respectively within 2 years. In eyes with a history of hypotony 
(≤5mmHg) in the ipsilateral or contralateral eye the lowered trend to develop IOP elevation 
was either not found or was inconsistent across both crude and adjusted analyses.
In contrast to the results of the prevalence analysis, eyes that developed diminished visual 
acuity during the course of follow-up were observed to have a minimally higher crude 
hazard of developing IOP elevation but the significance of the association was not sustained 
when other factors were accounted for (all adjusted P values>0.1).
As in the prevalence analysis, higher grade current activity of inflammation was inversely 
associated with IOP elevation, such that pediatric eyes with no or low grade (+0.5) anterior 
chamber cells demonstrated a similar hazard of incident IOP elevation whereas eyes with 
increasing grades of anterior chamber cells (≥1+) were progressively less likely to 
demonstrate such risk (all P values≤ 0.005). The association of IOP elevation with vitreous 
cells and haze and keratic precipitates was not found to be significant in children. Although 
eyes of children having snowballs were noted to be less likely to develop IOP≥21and 
10mmHg rise in the crude analyses, this association did not persist after accounting for other 
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factors. Regarding structural complications of uveitis, eyes with peripheral anterior and 
posterior synechia were not consistently associated with incident IOP elevation. Eyes with 
band keratopathy were ~2-fold more likely to develop IOP≥30mmHg (adjusted hazard 
ratio≥30mmHg[aHR30]=1.082.063.90, P=0.02) and were found to have a higher crude hazard 
to develop IOP elevations of ≥21 and 10mmHg rise (the latter two associations became non-
significant when other variables were accounted for).
Eyes of children on immunosuppressive therapy did not demonstrate increased hazard of 
IOP elevation (all adjusted P values>0.1). Regarding systemic corticosteroids, eyes of 
children receiving >7.5mg/day of prednisone (or equivalent) had a higher crude risk of 
developing IOP elevation when compared with eyes of children receiving ≤7.5mg/day or not 
on systemic corticosteroids, but the difference was no longer significant on accounting for 
other covariates.
Eyes treated with local corticosteroids were noted to have a strong risk for developing IOP 
elevation in a dose- and route of administration-dependent manner. Even eyes on 2–3 
drops/day of prednisolone acetate 1% (or equivalent alternative topical corticosteroids) 
demonstrated a 2- to 3-fold increased incidence of IOP elevation, the relative hazard 
reaching up to 4- to 9-fold when drops were being instilled ≥4 times/day (P<0.001). The risk 
of IOP elevation was progressively higher with increased frequency of drop instillation 
similar to that noted during prevalence analysis. Eyes that had received periocular 
corticosteroid injections had a 7-to 8-fold hazard of IOP elevation (aHR21=4.297.9614.7, 
aHR30=2.717.5420.9, aHR10=3.287.3116.3; each P<0.001); the risk being similar to that 
observed with the application of higher frequency of topical prednisolone acetate 1% (or 
equivalent alternative topical corticosteroid) drops. Use of intraocular corticosteroids was 
rare in this cohort, but when observed was associated with a very high risk of IOP elevation 
(aHR21=1.416.9634.2, P=0.02; aHR30=2.5518.1129, P=0.004; aHR10=4.4519.786.8, P<0.001) 
(See figure 3).
A sensitivity analysis regarding incident IOP elevation limited to eyes where IOP had been 
measured using applanation tonometry yielded similar results.
Discussion
Our results demonstrate that IOP elevation affects a large minority of children with non-
infectious uveitis, and identifies several risk factors. These observations potentially allow 
clinicians to minimize exposure to avoidable risk factors and to closely monitor high-risk 
eyes with risk factors that cannot be modified. The strongest risk factors identified for IOP 
elevation by this analysis, included eyes of children with contralateral IOP elevation and the 
use of local corticosteroids.
The observation that uveitic eyes of children whose contralateral eyes exhibited IOP 
elevation and/or required IOP-lowering therapy had a several-fold risk of IOP elevation may 
be the result of shared genetic and environmental exposures between the two eyes.
The high risk of IOP elevation in uveitic eyes of children receiving local corticosteroids 
noted in the study, is consistent with reports from other studies. 9,23,24 Our study further 
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characterized the degree of risk across a range of topical corticosteroid dosages as well 
across alternative methods of local corticosteroid administration, adjusting for other factors 
including the current grade of anterior chamber inflammatory cells (which might be affected 
by use of corticosteroids). Our results suggest that the risk of IOP elevation on the 
equivalent of one drop of prednisolone acetate 1% daily is not especially high in children, as 
it was elevated only in the prevalence analysis for IOP≥30 mmHg, and not in the incidence 
analyses. However, even dosages equivalent to 2 drops daily of prednisolone acetate 1% 
consistently were associated with 2- to 4-fold increased risk, and risk progressively 
increased with increasing dose, with ~9-fold increase noted with frequency of instillation 
greater than 8 drops per day. The risk associated with periocular corticosteroid use was 
similar to or marginally more than that associated with high dose topical prednisolone 
acetate 1% (or equivalent alternative topical corticosteroid) therapy. This might reflect a 
similar or slightly higher degree of drug delivery to the region of the trabecular meshwork 
when a depot is placed deep in the orbit, even though a large amount of corticosteroids are 
administered with longer bioavailability. Intraocular corticosteroid therapy was associated 
with a very high level of risk of IOP elevation (~100% by two years), probably because of a 
high level of access of the drug to the trabecular meshwork over a longer period of time. In 
contrast, use of systemic corticosteroids was not strongly associated with elevated IOP, 
particularly if the daily dose was 7.5 mg/day (prednisone or prednisone equivalent) or less, 
in which case the risk was similar to or less than that of patients not taking oral 
corticosteroids, probably because of low levels of drug delivery to the trabecular meshwork.
IOP elevation with corticosteroid use has been reported to occur within hours, but typically 
takes weeks to develop. The cumulative effect of local and systemic corticosteroids that 
might cause an IOP elevation in the long-run (possibly take years to develop) could not 
studied by us. 24–27 Corticosteroids have been known to induce changes in trabeculocytes 
and functional and structural (F-actin CLAN cytoskeletal structure, extracellular matrix 
myocilin deposition trabecular meshwork-induced glucocorticoid response protein-1 causing 
cell death) changes in the trabecular meshwork that increase outflow resistance. 15,24,25 Also 
glucocorticoid responsiveness in corticosteroid responders has been attributed to 
overexpression of glucocorticoid receptor GFβ isoform when compared to GFα. 28 
Corticosteroids have been reported to cause accelerated ocular hypertension with a rapidly 
pronounced, severe and more frequent IOP elevation in children, the analysis of which was 
outside the scope of this study. 29,30 Varying the placement of corticosteroids in and around 
the eye and the route of administration might determine their differential bioavailability in 
the aqueous and vitreous and might affect IOP elevation differently. 31 Perhaps the 
proximity of corticosteroids to the trabecular meshwork (depending on whether the 
periocular corticosteroids were injected by the subconjunctival or peribulbar route), 32 
duration of contact time with the trabecular meshwork and repository nature of the 
formulation itself may determine the extent and duration of IOP elevation. Our retrospective 
study did not allow direct assessment of these hypotheses.
In contrast to corticosteroids, immunosuppressive drug therapy was not associated with IOP 
elevation, even though one might have expected a selection bias in that more severely 
affected eyes would be more likely to receive such therapy. This observation suggests that 
use of corticosteroid-sparing therapy could be a useful strategy to help to avoid IOP 
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elevation in eyes that require long-term therapy for intraocular inflammation. However, 
because of the slower onset of action of immunosuppressive agents and the morbidity 
associated with ocular inflammation; corticosteroids likely will continue to play an 
important therapeutic role. Our results suggest that corticosteroid use requires careful 
monitoring at appropriate intervals to detect IOP elevation at a sufficiently early stage to 
allow timely intervention, and that long-term corticosteroid use should be minimized.
Regarding other potential risk factors, the absolute risk of IOP elevation in JIA-associated 
uveitic eyes was 34% by two years, a level near the high end of the distribution in our 
study’s overall pediatric uveitis population. Previous reports from subsets of patients at one 
of our participating centers have had similar results (most patients from which and several 
others were included in the current analysis). 33–35 However, JIA itself did not seem to have 
large direct effects on the risk of IOP elevation, suggesting that the presence of the other 
factors identified would be more predictive of risk in this population than the presence of 
JIA itself. Some previous reports that included adults, had observed eyes with 
Adamantiades-Behcet’s Disease-associated uveitis 36 to have a higher and HLA-B27 
positivity related uveitis 37,38 to have a lower incidence of IOP elevation. We did not 
observe any consistent associations of IOP elevation with HLA-B27, Adamantiades-
Behcet’s Disease, hypertension and sarcoidosis. All of these are diseases typically of adult 
onset, 36–38 and were observed to occur infrequently in the current study, limiting the power 
to detect moderate associations.
Eyes that had undergone cataract surgery prior to presentation for subspecialty care were 
more likely to present with IOP elevation, but eyes that had cataract surgery performed 
either previous to or during follow-up were not found to be associated with increased risk; a 
pattern for which several potential explanations are possible. Perhaps good perioperative 
inflammatory control and the availability of resources to manage intra- and post-operative 
complications under subspecialty care might explain this difference. Alternatively, cataract 
(leading to cataract surgery) might have served as an indicator of a greater extent of 
inflammatory damage at presentation, 39 which may not have been detectable after those 
eyes presenting with IOP elevation were removed from the at risk pool of the incidence 
analyses. It also could reflect regression to the mean if IOP elevation was a factor provoking 
referral. Eyes that had undergone pars plana vitrectomy tended to have both a higher 
prevalence and incidence of IOP elevation, which might be explained on the basis of 
increased disease severity among eyes requiring vitrectomy. The same relationship might 
underlie the association between band keratopathy and increased risk of IOP elevation.
Several eye-specific factors such as worse visual acuity, unilateral uveitis and uveitis of 
duration ≥6 months were associated with presenting IOP elevation but were not associated 
with increased incidence of IOP elevation during follow-up. These differences might reflect 
regression to mean if IOP was the reason for referral in these subsets. Also, all eyes that had 
an outcome at baseline (potentially eyes with worse disease on average) were not included 
in the incidence analysis, which may explain this difference between associations with 
prevalent and incident IOP elevation. Alternatively, ongoing inflammatory damage might 
have been stabilized by tertiary care, which could explain why we did not observe ongoing 
increased risk during follow-up.
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We did not note a consistent predilection to IOP elevation based on the anatomical location 
of uveitis, other than a weak indication suggesting lower risk with intermediate uveitis, 
which may reflect similar risk over the long-run across the various sites of inflammation. 
However, the inverse relationship between current anterior segment inflammatory findings 
and risk of IOP elevation may reflect a short-run anatomical effect in that lower IOP may be 
caused by current ciliary body inflammation. Our results suggest that in children current 
vitreous inflammation activity is not strongly associated with an alteration in the risk of IOP 
elevation. IOP elevation or hypotony might occur in relationship to the chronicity and 
severity of uveitic inflammatory processes that affect aqueous humor dynamics, 40 as 
indicated by associations noted with structural markers of inflammation. Also, eyes that had 
experienced hypotony either in the same or the contralateral eye inconsistently demonstrated 
a lower risk of IOP elevation. Perhaps hypotony, which might reflect damage to the ciliary 
body in excess of damage to the outflow pathways, is a long-run effect hence observed 
infrequently in our study.
All limitations of a retrospective design are applicable to our study, including potential 
selection bias and cohort effects. Our results are likely representative of IOP elevation 
patterns at tertiary centers (referral centers for complicated pediatric uveitis patients) but 
might overestimate the risk in a ‘general’ population. Data to study the risk of IOP elevation 
associated with presence of aqueous flare, which has been reported elsewhere as a risk 
factor, 41 were not available. The effect of measurement error related to inter-tonometric 
method variability and IOP correction factors based on age, 42 ocular characteristics in 
children and anesthesia among others also should be considered. However, these limitations 
seem unlikely to bias results sufficiently to result in false associations of the large magnitude 
observed. If the high dose corticosteroid effect on IOP persists for a few weeks, the risk 
associated with lower doses of corticosteroids might have been overestimated somewhat: 
eyes receiving higher doses shortly before the point of observation might have had higher 
risk than eyes consistently receiving the same dose, but both would be counted as on the 
same dose at the time of observation using the method that was possible with our 
retrospective data. If so, the consistent dose-response relationship observed might have been 
even more pronounced. The study did not evaluate the effect of difluprednate 0.005%, 
which was not available at the time of the study, but may be associated with higher risk of 
IOP elevation than alternative corticosteroid drops. 43 Not all eyes that required IOP-
lowering therapy might have experienced IOP elevations ≥30 and ≥10mmHg rise; thus the 
risk for these IOP outcomes may have been IOP over-estimated, although the approach 
would provide a reasonable estimate of the number of cases requiring treatment for IOP 
elevation. The rationale for our approach is that many outcomes likely would have occurred 
without treatment, and ignoring this possibility would have resulted in highly informative 
censoring, an important violation of the assumptions of the survival analysis method. 
Although with multiple comparisons and a Type 1 error threshold of 5%, some associations 
could have been due to chance, in an exploratory observational study, penalization of the 
Type 1 error probability for multiple comparisons is not recommended, 44 and in any case 
the strength of the relationship (P<0.001) noted with most positive associations would be 
robust to multiplicity concerns. Strengths of the study include the statistical advantages of its 
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large sample size and data collection under a common study protocol across multiple 
centers.
In summary, IOP elevation affects a large minority of pediatric uveitis cases, suggesting that 
such eyes should be monitored for IOP elevation. Patients who experience such elevation in 
one uveitic eye are highly likely to experience it in the other eye, and should be monitored 
especially closely. The use of topical corticosteroids at a dose of more than 1 drop of 
prednisolone acetate 1% per day, as well as periocular and particularly intraocular 
corticosteroids, are associated with large increases in the risk of IOP elevation, with very 
high risks associated with high dosages of topical corticosteroids, periocular and 
intravitreous corticosteroids. Particularly close follow-up when treating active inflammation 
is warranted, as our results suggest that the use of large amounts of corticosteroids and the 
resolution of anterior chamber inflammation both are associated with an increased risk of 
IOP elevation. Since topical corticosteroids are associated with increased risk in a dose-
response relationship, it is important to balance use of sufficient doses to quickly quell 
inflammation with use of a low enough dose (or sufficiently short duration of high dose 
therapy) to minimize the risk of IOP elevation. Prompt inflammatory control, corticosteroid-
sparing strategies when chronic corticosteroid therapy is required, and early subspecialty 
involvement for complex cases might help improve outcomes. Further research regarding 
the functional outcomes of IOP elevation in this context would help to elucidate these results 
and determine whether certain interventions are more effective than others.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Time-to-event estimate demonstrating the cumulative incidence (95% CI*) of IOP elevation 
in pediatric non-infectious uveitis over a 5-year follow-up period. >20% of eyes were 
estimated to have a visit with IOP≥30 mmHg within five years. Although the rate of 
incidence of IOP elevation in pediatric non-infectious uveitic eyes declines with time under 
subspecialty care, the cumulative incidence increases over time. The shaded areas around 
the time-to-event curves represent 95% confidence intervals.
CI*-Confidence interval
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Risk of incident IOP elevation in pediatric non-infectious uveitis when the contralateral eye 
experienced IOP elevation or was on active IOP-lowering drops or surgery. A dose-
dependent pattern was noted.
CI*-Confidence interval
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Risk of incident IOP elevation associated with corticosteroid use in pediatric non-infectious 
uveitis demonstrating the dose-and route of administration-dependent response. Systemic 
corticosteroids refer to doses for prednisone or an equipotent dose of an alternative 
corticosteroid. Topical corticosteroids refer to the number of drops per day of prednisolone 
acetate 1% or an equipotent dose of an alternative topical corticosteroid. Periocular and 
intraocular corticosteroids typically included dosages of 40 mg and 4 mg of triamcinolone 
acetonide, respectively.
CI*-Confidence interval
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